CompanyGraph
Tianjin Chase Sun Pharmaceutical Co., Ltd.
300026 · SZSE · China
chasesun.cnFinancials as of FY2024–FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.43B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.07: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.31%Below 5Y avg (0.73%)
Annual Rate
CNY 0.01Paid annual
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jul 15, 2026
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2025, balance sheet FY2024, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
9.61BCNY1.43B · vs all stocks (USD)
Trailing P/E
320.00xRevenue (TTM)
4.33BCNY646.74M · vs all stocks (USD)
Profit Margin
0.41%Beta
0.0250xvs all stocks
52-Week Change
-14.67%vs all stocks
Market Capitalization
9.61BCNY1.43B · vs all stocks (USD)
Enterprise Value
8.45BCNY1.26B · vs all stocks (USD)
Trailing P/E
320.00xForward P/E
7.80xPrice to Sales (TTM)
2.22xPrice to Book (MRQ)
1.12xEnterprise to Revenue
1.95xEnterprise to EBITDA
18.95xGross Margin
56.51%Profit Margin
0.41%Operating Margin
2.98%Return on Assets (TTM)
1.06%Return on Equity (TTM)
0.24%Revenue (TTM)
4.33BCNY646.74M · vs all stocks (USD)
Revenue per Share (TTM)
2.35CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-24.60%Gross Profit (TTM)
2.56BCNY382.20M · vs all stocks (USD)
EBITDA (TTM)
305.23MCNY45.55M · vs all stocks (USD)
Net Income (TTM)
17.95MCNY2.68M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-32.40%Operating Cash Flow (TTM)
785.90MCNY117.27M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
784.42MCNY117.05M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0100CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.31%vs all stocks
5-Year Average Dividend Yield
0.73%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
154.66MCNYFY2024 · Dec 31, 2024EPS (Basic)
0.0100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.85BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.85BSharesFY2025 · Dec 31, 2025Operating Cash Flow
161.73MCNYFY2024 · Dec 31, 2024Free Cash Flow
-31.00MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
1.27BCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
22.95MCNYFY2024 · Dec 31, 2024Other Non-cash Items
68.15MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-10.92MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
81.56MCNYFY2024 · Dec 31, 2024Capital Expenditures
-192.73MCNYFY2024 · Dec 31, 2024Sale of Investments
6.79MCNYFY2024 · Dec 31, 2024Other Investing Activity
15.67MCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
-170.26MCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
56.51MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-814.67MCNYFY2024 · Dec 31, 2024Common Dividends Paid
-137.11MCNYFY2024 · Dec 31, 2024Other Financing Charges
-57.37MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
-952.64MCNYFY2024 · Dec 31, 2024Shares Outstanding
3.00BSharesUpdated Sep 20, 2026Float Shares
1.90BSharesUpdated Sep 20, 2026% Held by Insiders
42.97%vs all stocks
% Held by Institutions
1.89%vs all stocks
Total Cash (MRQ)
1.68BCNY250.05M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5580CNYUpdated Sep 20, 2026Total Debt (MRQ)
386.24MCNY57.63M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0445xCurrent Ratio (MRQ)
4.37xBook Value per Share (MRQ)
2.85CNYUpdated Sep 20, 2026Total Assets
11.17BCNY1.67B · vs all stocks (USD)
Total Current Assets
6.15BCNYFY2024 · Dec 31, 2024Total Liabilities
2.37BCNYFY2024 · Dec 31, 2024Total Non-current Assets
5.02BCNYFY2024 · Dec 31, 2024Total Non-current Liabilities
745.41MCNYFY2024 · Dec 31, 2024Total Current Liabilities
1.62BCNYFY2024 · Dec 31, 2024Cash
1.26BCNYFY2024 · Dec 31, 2024Cash Equivalents
50.51MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents
1.31BCNYFY2024 · Dec 31, 2024Accounts Receivable
2.66BCNYFY2024 · Dec 31, 2024Inventory
1.75BCNYFY2024 · Dec 31, 2024Accounts Payable
678.15MCNYFY2024 · Dec 31, 2024Short-term Debt
211.74MCNYFY2024 · Dec 31, 2024Other Current Liabilities
7.08MCNYFY2024 · Dec 31, 2024Long-term Debt
640.33MCNYFY2024 · Dec 31, 2024Common Stock (Book)
3.00BCNYFY2024 · Dec 31, 2024Retained Earnings
4.74BCNYFY2024 · Dec 31, 2024Total Shareholders' Equity
8.80BCNY1.31B · vs all stocks (USD)
52-Week Low
2.82CNYUpdated Sep 20, 202652-Week High
3.99CNYUpdated Sep 20, 202652-Week Change
-14.67%vs all stocks
Beta
0.0250xvs all stocks
50-Day MA
3.38CNYUpdated Sep 20, 2026200-Day MA
3.44CNYUpdated Sep 20, 2026Avg 10-Day Volume
37.23MSharesUpdated Sep 20, 2026Avg 30-Day Volume
74.34MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.0100CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: 0.00
Financial Health
Altman Z-Score 4.07: safe zoneNotable
Altman Z-Score: 4.07
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.43B, above the global median of $1.18BNotable
Market cap (USD): 1,434,495,951.227Global Median: 1,180,223,658.953
Revenue is $646.74M, above the global median of $548.88MNotable
Revenue (USD): 646,735,772.436Global Median: 548,883,780.48
Levered free cash flow is $117.05M, above the global median of $18.73MNotable
Levered free cash flow (USD): 117,051,749.28Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk